{
    "clinical_study": {
        "@rank": "144884", 
        "arm_group": {
            "arm_group_label": "Positron Emission Tomography", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive fludeoxyglucose F 18 IV. Approximately 1 hour later, patients undergo positron emission tomography imaging. Some patients may undergo a repeat scan in 4-6 months."
        }, 
        "brief_summary": {
            "textblock": "RATIONALE: Imaging procedures such as positron emission tomography (PET) may improve the\n      ability to detect the extent of breast cancer.\n\n      PURPOSE: Diagnostic trial to study the effectiveness of PET to detect the extent of breast\n      cancer in women who have primary or recurrent breast cancer."
        }, 
        "brief_title": "Positron Emission Tomography Before Surgery in Evaluating Women With Primary or Recurrent Breast Cancer", 
        "completion_date": {
            "#text": "February 2009", 
            "@type": "Actual"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the sensitivity, specificity, and accuracy of fludeoxyglucose F 18 (FDG)\n           positron emission tomography (PET) as compared to conventional imaging in determining\n           the extent of disease in women with primary or recurrent breast cancer.\n\n        -  Determine how often clinical management and operative intervention plans for patients\n           are altered based on these FDG-PET scan findings.\n\n        -  Determine whether FDG-PET results in more accurate detection of disease in these\n           patients.\n\n      OUTLINE: Patients receive fludeoxyglucose F 18 IV. Approximately 1 hour later, patients\n      undergo positron emission tomography imaging. Some patients may undergo a repeat scan in 4-6\n      months.\n\n      PROJECTED ACCRUAL: (50 with primary disease and 50 with recurrent disease) will be accrued\n      for this study within 1-2 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Diagnosis of breast cancer for which surgical intervention is planned\n\n               -  Large primary breast cancer (i.e., larger than 5 cm, T3) as determined by prior\n                  biopsy, physical exam, or mammogram OR\n\n               -  Locally advanced breast cancer (T4) OR\n\n               -  Clinical suspicion of axillary nodal disease (N1-2) (i.e., stage IIB-IIIA) OR\n\n               -  Locally or regionally recurrent disease\n\n          -  No locally recurrent disease that is non-invasive (i.e., ductal carcinoma in situ)\n\n          -  No locally advanced disease (e.g., inflammatory breast cancer) that will be treated\n             with neoadjuvant chemotherapy without surgery\n\n          -  Hormone receptor status:\n\n               -  Not specified\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  Not specified\n\n        Sex:\n\n          -  Female\n\n        Menopausal status:\n\n          -  Not specified\n\n        Performance status:\n\n          -  Not specified\n\n        Life expectancy:\n\n          -  Not specified\n\n        Hematopoietic:\n\n          -  Not specified\n\n        Hepatic:\n\n          -  Not specified\n\n        Renal:\n\n          -  Not specified\n\n        Other:\n\n          -  No other malignancy except previously treated nonmelanoma skin cancer or carcinoma in\n             situ of the cervix\n\n          -  No known active infection\n\n          -  No autoimmune disease or inflammatory disease (e.g., sarcoidosis or rheumatoid\n             arthritis)\n\n          -  Able to fast for 6 hours and tolerate a FDG-PET scan for the duration of the test\n\n          -  Not pregnant or nursing\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  Not specified\n\n        Chemotherapy:\n\n          -  See Disease Characteristics\n\n        Endocrine therapy:\n\n          -  Not specified\n\n        Radiotherapy:\n\n          -  Not specified\n\n        Surgery:\n\n          -  See Disease Characteristics"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "118", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 6, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00039286", 
            "org_study_id": "01-134", 
            "secondary_id": [
                "P30CA008748", 
                "MSKCC-01134", 
                "NCI-G02-2074"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Positron Emission Tomography", 
                "intervention_name": "positron emission tomography", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Positron Emission Tomography", 
                "intervention_name": "radionuclide imaging", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Positron Emission Tomography", 
                "intervention_name": "fludeoxyglucose F 18", 
                "intervention_type": "Radiation"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "stage II breast cancer", 
            "stage IIIA breast cancer", 
            "recurrent breast cancer"
        ], 
        "lastchanged_date": "April 17, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/MSKCC-01134"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10021"
                }, 
                "name": "Memorial Sloan-Kettering Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Pilot Study To Assess The Utility Of 18F-Fluorodeoxyglucose Positron Emission Tomography (PET) In The Pre-Operative Evaluation Of Patients With Primary And Recurrent Breast Carcinoma", 
        "overall_official": {
            "affiliation": "Memorial Sloan-Kettering Cancer Center", 
            "last_name": "Elisa Rush Port, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2009", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Determine the sensitivity, specificity, and accuracy", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00039286"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Memorial Sloan-Kettering Cancer Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Memorial Sloan-Kettering Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2001", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }, 
    "geocoordinates": {
        "Memorial Sloan-Kettering Cancer Center": "40.714 -74.006"
    }
}